http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2762493-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d584042a524740a406723fe1631e49e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 |
| filingDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12900f4661dce158842f795b620c4e6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aef8da63adc119a07472c085b5b95b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e87f35d668e9432134637f1e65619663 |
| publicationDate | 2021-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2762493-C1 |
| titleOfInvention | Method for preoperative prediction of the risk of recurrence in patients with stage t1 endometrial cancer |
| abstract | FIELD: oncology and molecular biology.SUBSTANCE: invention relates to oncology and molecular biology. In the preoperative period, venous blood is examined by multicolor flow cytometry using monoclonal antibodies to EpCam, CD45, CD44, CD24, N-Cadherin labeled with various fluorochromes, and NucBlue Live cell stain ready probes reagent nuclear dye. Then determine the number of Epcam + CD45- (cells/ml of blood) (X1), the number of CTCs with the Epcam + CD45-CD44-CD24-Ncadherin + phenotype (cells/ml) (X2), the number of stem CTCs without Epcam expression on the membrane with the Epcam phenotype (m) -CD45-CD44 + CD24- (cells/ml) (X3); the number of atypical/hybrid forms of CTCs with the Epcam + CD45 + phenotype (cells/ml) (X4). Then the value of the regression equation Υ is calculated according to the original formula. At Υ≥0.5, a high is determined, and at Υ<0.5, a low risk of endometrial cancer recurrence is determined.EFFECT: method allows to reduce invasiveness and increase the accuracy, sensitivity and specificity of the method by 87.5% and 96.7%, respectively.1 cl, 2 tbl, 2 ex |
| priorityDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 96.